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Abstract
Tuberculosis (TB) and human immunodeficiency virus (HIV) can be considered a deadly
human syndemic. In this article, we formulate a model for TB and HIV transmission dy-
namics. The model considers both TB and acquired immune deficiency syndrome (AIDS)
treatment for individuals with only one of the infectious diseases or both. The basic repro-
duction number and equilibrium points are determined and stability is analyzed. Through
simulations, we show that TB treatment for individuals with only TB infection reduces the
number of individuals that become co-infected with TB and HIV/AIDS, and reduces the
diseases (TB and AIDS) induced deaths. Analogously, the treatment of individuals with
only AIDS also reduces the number of co-infected individuals. Further, TB-treatment for
co-infected individuals in the active and latent stage of TB disease, implies a decrease of the
number of individuals that passes from HIV-positive to AIDS.
Keywords: Tuberculosis, Human immunodeficiency virus, Syndemic, Treatment, Equilibrium,
Stability.
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1 Introduction
Tuberculosis (TB) and human immunodeficiency virus/acquired immune deficiency syndrome
(HIV/AIDS) are the leading causes of death from an infectious disease worldwide [16]. Individuals
infected with HIV are more likely to develop TB disease because of their immunodeficiency, and
HIV infection is the most powerful risk factor for progression from TB infection to disease [7]. This
interaction justifies the fact that HIV and TB can be considered a deadly human syndemic, where
syndemic refers to the convergence of two or more diseases that act synergistically to magnify the
burden of disease [10].
Following UNAIDS global report on AIDS epidemic 2013 [14], globally, an estimated 35.3
million people were living with HIV in 2012. An increase from previous years, as more people are
receiving the life-saving antiretroviral therapy (ART). There were approximately 2.3 million new
HIV infections globally, showing a 33% decline in the number of new infections with respect to
2001. At the same time, the number of AIDS deaths is also declining with around 1.6 million AIDS
deaths in 2012, down from about 2.3 million in 2005. In 2012, 1.1 million of 8.6 million people who
developed TB worldwide were HIV-positive. The number of people dying from HIV-associated
TB has been falling since 2003. However, there were still 320 000 deaths from HIV-associated TB
in 2012 and further efforts are needed to reduce this burden [16]. ART is a critical intervention
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for reducing the risk of TB morbidity and mortality among people living with HIV and, when
combined with isoniazid preventive therapy, it can have a significant impact on TB prevention
[16].
Collaborative TB/HIV activities (including HIV testing, ART therapy and TB preventive
measures) are crucial for the reduction of TB-HIV coinfected individuals. The World Health
Organization (WHO) estimates that these collaborative activities prevented 1.3 million people from
dying, from 2005 to 2012. However, significant challenges remain: the reduction of tuberculosis
related deaths among people living with HIV has slowed in recent years; the ART therapy is not
being delivered to TB-HIV coinfected patients in the majority of the countries with the largest
number of TB/HIV patients; the pace of treatment scale-up for TB/HIV patients has slowed; less
than half of notified TB patients were tested for HIV in 2012; and only a small fraction of TB/HIV
infected individuals received TB preventive therapy [14].
The study of the joint dynamics of TB and HIV present formidable mathematical challenges
due to the fact that the models of transmission are quite distinct [12]. Few mathematical models
have been proposed for TB-HIV coinfection (see, for example, [1, 9, 11, 12, 13]). Kirschner
[9] developed a cellular model for HIV-1 and TB coinfection inside a host. Roeger et al. [12]
proposed a population model for TB-HIV/AIDS coinfection transmission dynamics, assuming
that TB-infected individuals in the active stage of the disease are too ill to remain sexually active
and therefore they are unable to transmit HIV. In this work we assume that active TB-infected
individuals are susceptible to HIV-infection. Naresh and Tripathi [11] proposed a model for TB-
HIV coinfection in a variable size population with only TB treatment. Here we consider TB and
HIV treatment in different stages of the disease. Bhunu et al. [1] studied a TB-HIV coinfection
model with both TB and HIV treatment. The authors did not take into account that an individual
co-infected with TB and HIV can effectively recover from TB infection. We assume that TB can be
cured, even in HIV-positive individuals [16]. Sharomi et al. [13] also considered these assumptions,
subdividing the total population into 15 classes. It is our aim in this work to develop a model
that balances two goals: simplicity and useful information.
The paper is organized as follows. Section 2 describes our model for TB-HIV syndemic with
TB and HIV treatment. In Section 3 the positivity and boundedness of solutions of the model
are proved and in Section 4 equilibrium points and respective stability are analyzed. Section 5 is
devoted to numerical simulations and discussion of results.
2 TB-HIV/AIDS model
The model subdivides the human population into 10 mutually-exclusive compartments, namely
susceptible individuals (S), TB-latently infected individuals, who have no symptoms of TB disease
and are not infectious (LT ), TB-infected individuals, who have active TB disease and are infectious
(IT ), TB-recovered individuals (RT ), HIV-infected individuals with no clinical symptoms of AIDS
(IH), HIV-infected individuals with AIDS clinical symptoms (A), TB-latent individuals co-infected
with HIV (pre-AIDS) (LTH), HIV-infected individuals (pre-AIDS) co-infected with active TB
disease (ITH), TB-recovered individuals with HIV-infection without AIDS symptoms (RTH), HIV-
infected individuals with AIDS symptoms co-infected with TB (AT ). The total population at time
t, denoted by N(t), is given by
N(t) = S(t) + LT (t) + IT (t) +RT (t) + IH(t) +A(t) + ITH(t) + LTH(t) +RTH(t) +AT (t) .
The susceptible population is increased by the recruitment of individuals (assumed susceptible)
into the population, at a rate Λ. All individuals suffer from natural death, at a constant rate µ.
Susceptible individuals acquire TB infection from individuals with active TB at a rate λT , given
by
λT =
β1
N
(IT + ITH +AT ) ,
2
where β1 is the effective contact rate for TB infection. Similarly, susceptible individuals acquire
HIV infection, following effective contact with people infected with HIV at a rate λH , given by
λH =
β2
N
[IH + ITH + LTH +RTH + η (A+AT )] ,
where β2 is the effective contact rate for HIV transmission and the modification parameter η > 1
accounts for the relative infectiousness of individuals with AIDS symptoms, in comparison to those
infected with HIV with no AIDS symptoms. Individuals with AIDS symptoms are more infectious
than HIV-infected individuals (pre-AIDS) because they have a higher viral load and there is a
positive correlation between viral load and infectiousness [5].
Individuals leave the latent-TB class LT by becoming infectious, at a rate k1, or recovered,
with a treatment rate τ1. The treatment rate for active TB-infected individuals is τ2. We assume
that TB-recovered individuals RT acquire partial immunity and the transmission rate for this class
is given by β′1λT with β
′
1 6 1. Individuals with active TB disease suffer induced death at a rate
dT . We assume that individuals in the class RT are susceptible to HIV infection at a rate λH . On
the other hand, TB-active infected individuals IT are susceptible to HIV infection, at a rate δλH ,
where the modification parameter δ > 1 accounts for higher probability of individuals in class IT
to become HIV-positive.
HIV-infected individuals (with no AIDS symptoms) progress to the AIDS class A, at a rate
ρ1. HIV-infected individuals with AIDS symptoms are treated for HIV at the rate α1 and suffer
induced death at a rate dA. Individuals in the class IH are susceptible to TB infection at a rate
ψλT , where ψ > 1 is a modification parameter traducing the fact that HIV infection is a driver of
TB epidemic [10].
HIV-infected individuals (pre-AIDS) co-infected with TB-disease, in the active stage ITH , are
treated for TB at the rate τ3 and progress to the AIDS-TB co-infection class AT at a rate ρ2.
Individuals in the class ITH suffer TB induced death at a rate dT . The anti-TB drugs can prevent
or decrease the likelihood of TB infection progression to active TB disease in individuals in the
class LTH [17]. The treatment rate for individuals in this class is given by τ4. However, individuals
in the class LTH are more likely to progress to active TB disease than individuals infected only
with latent TB. In our model, this progression rate is given by k2. Similarly, HIV infection makes
individuals more susceptible to TB reinfection when compared with non HIV-positive patients.
The modification parameter associated to the TB reinfection rate, for individuals in the class RTH ,
is given by β′2, where β
′
2 > 1. Individuals in this class progress to class AT , at a rate ρ3.
HIV-infected individuals (with AIDS symptoms), co-infected with TB, are treated for HIV, at
a rate α2. Individuals in the class AT suffer from AIDS-TB coinfection induced death rate, at a
rate dTA.
The aforementioned assumptions result in the following system of differential equations that
describes the transmission dynamics of TB and HIV disease:

S˙(t) = Λ− λTS(t)− λHS(t)− µS(t),
L˙T (t) = λTS(t) + β
′
1λTRT (t)− (k1 + τ1 + µ)LT (t),
I˙T (t) = k1LT (t)− (τ2 + dT + µ+ δλH)IT (t),
R˙T (t) = τ1LT (t) + τ2IT (t)− (β
′
1λT + λH + µ)RT (t),
I˙H(t) = λHS(t)− (ρ1 + ψλT + µ)IH(t) + α1A(t) + λHRT (t),
A˙(t) = ρ1IH(t)− α1A(t)− (µ+ dA)A(t),
L˙TH(t) = β
′
2λTRTH(t)− (k2 + τ4 + µ)LTH(t),
I˙TH(t) = δλHIT (t) + ψλT IH(t) + α2AT (t) + k2LTH(t)− (τ3 + ρ2 + µ+ dT )ITH(t),
R˙TH(t) = τ3ITH(t) + τ4LTH(t)− (β
′
2λT + ρ3 + µ)RTH ,
A˙T (t) = ρ2ITH(t) + ρ3RTH − (α2 + µ+ dTA)AT (t) .
(1)
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Figure 1: Model for TB-HIV/AIDS transmission with treatment.
The model flow is described in Figure 1. The initial conditions of model (1) satisfy
S(0) = S0 > 0 , LT (0) = LT0 > 0 , IT (0) = IT0 > 0 , RT (0) = RT0 > 0 ,
IH(0) = IH0 > 0 , A(0) = A0 > 0 , LTH(0) = LTH0 > 0 ,
ITH(0) = ITH0 > 0 , RTH(0) = RTH0 > 0 , AT (0) = AT0 > 0 .
(2)
Note that if we consider the sub-model of (1) with no HIV/AIDS disease, that is, IH = A =
LTH = ITH = RTH = AT = 0, then we obtain the TB model from [3]. On the other hand, if we
consider the sub-model with no TB, that is, LT = IT = RT = LTH = ITH = RTH = AT = 0,
then we obtain an HIV/AIDS model based on the models proposed in [1, 8].
3 Positivity and boundedness of solutions
Let (S,LT , IT , RT , IH , A, LTH , ITH , RTH , AT ) ∈ R
10
+ be any solution of (1) with initial conditions
(2). Consider the biologically feasible region given by
Ω =
{
(S,LT , IT , RT , IH , A, LTH , ITH , RTH , AT ) ∈ R
10
+ : 0 6 N(t) 6
Λ
µ
}
. (3)
For the model system (1) to be epidemiologically meaningful, it is important to prove that all its
state variables are nonnegative for all time t > 0. Suppose, for example, that at some t¯ > 0 the
variable LT becomes zero, i.e., LT (t¯) = 0, while all other variables are positive. Then, from the
LT equation we have dLT (t¯)/dt > 0. Thus, LT (t) > 0 for all t > 0. Analogously, we can prove
that all variables remain nonnegative for all time t > 0.
Adding all equations in model (1) gives
dN
dt
(t) = Λ− µN(t)− dT IT (t)− dAA(t) − dT ITH(t)− dTAAT (t) .
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Since N(t) > IT (t) +A(t) + ITH(t) +AT (t), then
Λ− (µ+ dT + dA + dTA)N(t) 6
dN
dt
(t) 6 Λ− µN(t) .
Therefore, we conclude that N(t) is bounded for all t > 0 and every solution of system (1) with
initial condition in Ω remains in Ω. This result is summarized below.
Lemma 3.1. The region Ω is positively invariant for the model (1) with non-negative initial
conditions in R10+ .
4 Stability analysis
The model (1) has four non-negative equilibria, namely
(i) The disease-free equilibrium (no disease)
Σ0 = (S0, LT0 , IT0 , RT0 , IH0 , A0, LTH0 , ITH0 , RTH0 , AT0) =
(
Λ
µ
, 0, 0, 0, 0, 0, 0, 0, 0, 0
)
. (4)
(ii) The HIV-AIDS free equilibrium
ΣT = (S
⋄, L⋄T , I
⋄
T , R
⋄
T , I
⋄
H , A
⋄, L⋄TH , I
⋄
TH , R
⋄
TH , A
⋄
T )
with I⋄T > 0 and I
⋄
H = A
⋄ = L⋄TH = I
⋄
TH = R
⋄
TH = A
⋄
T = 0 for R1 > 1, where R1 is the
basic reproduction number of the model (1) with IH = A = LTH = ITH = RTH = AT = 0
(only TB model) that is given by
R1 =
Λ
Nµ
(
β1
dT + µ+ τ2
)(
k1
k1 + τ1 + µ
)
(5)
(see [3]).
(iii) The TB-free equilibrium
ΣH = (S
⋆, L⋆T , I
⋆
T , R
⋆
T , I
⋆
H , A
⋆, L⋆TH , I
⋆
TH , R
⋆
TH , A
⋆
T )
with L⋆T = I
⋆
T = R
⋆
T = L
⋆
TH = I
⋆
TH = R
⋆
TH = A
⋆
T = 0 and
S⋆ =
Λ
µR2
, I⋆H = (R2−1)
µNH(α1 + dA + µ)
β2(α1 + dA + µ+ ηρ1)
, A⋆ = (R2−1)
ρ1µNH
β2(α1 + dA + µ+ ηρ1)
,
for R2 > 1, where R2 is the basic reproduction number of model (1) with LT = IT = RT =
LTH = ITH = RTH = AT = 0 (only HIV-AIDS model), that is,
R2 =
Λ
Nµ
β2
(
µ+ α1 + dA + η ρ1
µα1 + (µ+ ρ1)(µ+ dA)
)
. (6)
(iv) The syndemic equilibrium
Σ∗ = (S∗, L∗T , I
∗
T , R
∗
T , I
∗
H , A
∗, L∗TH , I
∗
TH , R
∗
TH , A
∗
T )
with I∗T > 0, I
∗
H > 0, A
∗ > 0, L∗TH > 0, I
∗
TH > 0, R
∗
TH > 0 and A
∗
T > 0, for R0 > 1, where
R0 is the basic reproduction number of the model (1), that is,
R0 = max{R1, R2} .
5
The details of the computation of the basic reproduction number R0 are given in Appendix A.
The following theorem states the stability of the equilibrium points.
Theorem 4.1. The disease free equilibrium Σ0 is locally asymptotically stable if R0 < 1, and
unstable if either Ri > 1 with i = 1, 2. The HIV-AIDS free equilibrium ΣT is locally asymptotically
stable if R1 > 1, and the TB-free equilibrium ΣH is locally asymptotically stable for R2 near 1.
Details of the proof of Theorem 4.1 are given in Appendix B.
Explicit expressions for the coinfection endemic equilibrium Σ∗ are very difficult to compute
analytically. In Section 5, we consider an example, with R0 > 1, for which there exists a syndemic
equilibrium, and analyze, numerically, the local asymptotical stability of the syndemic equilibrium
Σ∗.
5 Numerical analysis and discussion
For numerical simulations, we consider the following initial conditions for system (1):
(S(0), LT (0), IT (0), RT (0), IH(0), A(0), LTH(0), ITH(0), RTH(0), AT (0))
=
(
60N
100
,
14N
100
,
3N
100
, 0,
4N
100
,
N
100
,
12N
100
,
5N
100
, 0,
N
100
)
(7)
with N = 50000. The parameters of model (1) take the values of Table 1.
Symbol Value References Symbol Value References
Λ 714 τ4 1 yr
−1
µ 1/70 yr−1 ρ1 0.1 yr
−1 [18, 19]
β1 variable ρ2 0.25 yr
−1
β2 variable ρ3 0.125 yr
−1
β′1 0.9 α1 0.33 yr
−1 [1]
β′2 1.1 α2 0.33 yr
−1
k1 1 [3] ψ 1.07
k2 1.3 k1 [17] dT 1/8 yr−1
τ1 1 yr
−1 [3] dA 0.3 yr
−1
τ2 2 yr
−1 [3] dTA 0.33 yr
−1
τ3 2 yr
−1 η 1.02
δ 1.03
Table 1: Parameters of the TB-HIV/AIDS model (1).
5.1 Equilibrium points and stability analysis
In Table 2 we show the effect of the transmission coefficient β1 on the state I
⋄
T of the HIV-
free equilibrium ΣT and on the basic reproduction number R1. Table 3 shows the effect of the
transmission coefficient β2 on the states I
⋆
H and A
⋆ of the TB-free equilibrium ΣH and on the
basic reproduction number R2. We conclude that the equilibrium states I
⋄
T and (I
⋆
H , A
⋆) increase
with the transmission coefficients β1 and β2, respectively.
In Figure 2 we considered different initial conditions in a neighborhood of the initial conditions
given by (7) and R0 < 1 (R1 < 1 and R2 < 1) to illustrate the stability of the disease-free
6
β1 4.3 6 10 15 50
R1 0.99788 1.39239 2.32065 3.48097 11.60326
I⋄T 0.00397 903.93492 2206.57268 2870.72755 3804.50589
Table 2: Effect of β1 on I
⋄
T and R1.
β2 0.051 0.055 0.07 0.09 0.99
R2 0.93669 1.01016 1.28566 1.65299 1.81829
I⋆H 0.01708 135.73817 2516.54721 4472.84980 4930.48696
A⋆ 0.00266 21.07182 390.59491 694.23361 765.26396
Table 3: Effect of β2 on I
⋆
H , A
⋆ and R2.
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Figure 2: Stability of the disease-free equilibrium (4).
equilibrium Σ0 given by (4). In these numerical simulations we considered β1 = 2.7 and β2 = 0.03,
corresponding to R1 = 0.62632 and R2 = 0.55077, while the rest of the parameters take the values
in Table 1.
Figure 3 shows that, for R0 > 1, the syndemic equilibrium Σ
∗ exists. We considered different
initial conditions for the state variables of system (1) in a neighborhood of (7), β1 = 6 and
β2 = 0.1, corresponding to R1 = 1.39239 and R2 = 1.83593, and the rest of the parameters take
the values in Table 1. We observe that the state variables converge to Σ∗ when t → ∞. In this
case, Σ∗ is given by
Σ∗ = (S∗, L∗T , I
∗
T , R
∗
T , I
∗
H , A
∗, L∗TH , I
∗
TH , R
∗
TH , A
∗
T )
= (4766.84, 2019.66, 943.06, 28621.89, 362.66, 56.29, 31.39, 55.15, 495.68, 112.33) .
5.2 Treatment impact on TB-HIV/AIDS coinfection
Consider β1 = 13 and β2 = 0.06, while the rest of the parameters take the values of Table 1.
Figure 4 shows the impact of treating the individuals with active and latent TB on the number
of individuals co-infected with TB-HIV/AIDS. The treatment of individuals with only-TB, IT
and LT , has a positive impact on the reduction of the number of individuals co-infected with
TB-HIV/AIDS. Moreover, the number of individuals that suffered from disease (TB and AIDS)
induced death is higher when individuals with TB-single infection are not treated. In this case
7
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Figure 3: Stability of the syndemic equilibrium Σ∗.
the total population at the end of 20 years is around 10509 and, in the case where individuals
with only TB are treated, the total population at the end of 20 years is around 29758 individuals.
In Figure 5, we assume that there are no disease induced deaths, that is, dT = dA = dTA = 0.
The impact of treating individuals with only TB on the reduction of the number of individuals
co-infected is more evident. Figure 6 illustrates the case where we compare the number of
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Figure 4: Impact of TB treatment on single-infected individuals with disease induced death.
individuals co-infected with TB-HIV/AIDS when individuals with only AIDS symptoms AT are
or not treated. We observe that treating this class of individuals is important for the reduction
of the number of individuals that become co-infected, with special attention to the individuals
that have AIDS symptoms and TB infection. In figure 7, we considered that there is no disease
induced deaths (dT = dA = dTA = 0). It is crucial that TB-infected individuals (in the latent
and active stage), which are also HIV-positive, take anti-TB drugs, since they can recover from
TB. We analyze the impact of treating TB-HIV/AIDS co-infected individuals LTH , ITH and AT
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Figure 5: Impact of TB treatment on single-infected individuals with no disease induced death.
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Figure 6: Impact of AIDS treatment on single-infected individuals with disease induced death.
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Figure 7: Impact of AIDS treatment on single-infected individuals with no disease induced death.
on the reduction of the number of individuals coinfection. If anti-TB drugs are supplied, then
latent and active-TB individuals with HIV can recover and pass to the class RTH (the number
of individuals in the class RTH tends to zero when TB is not treated). In Figure 8, we observe
that after 7 years the number of individuals infected with active-TB and HIV, in the case without
treatment, becomes lower than in the case with treatment. This is due to the fact that coinfection
precipitates AIDS symptoms.
A Appendix: Computation of R0
The basic reproduction number represents the expected average number of new infections produced
by a single infectious individual when in contact with a completely susceptible population [15].
Following [15], the basic reproduction number R0 is obtained as the spectral radius of the matrix
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Figure 8: Impact of TB and AIDS treatment on co-infected individuals with no disease induced
death.
F · V −1 at the disease-free equilibrium Σ0, given by (4), with F =
[
F1 F2
]
and
F1 =


0 0 0 0 0
λT 0
β1S
N
+
β
′
1β1RT
N
β
′
1
λT 0
0 0 0 0 0
0 0 0 0 0
λH 0 0 λH
β2S
N
+ β2RT
N
0 0 0 0 0
0 0
β
′
2β1RTH
N
0 0
0 0 δλH +
ψβ1IH
N
0 δβ2IT
N
+ ψλT
0 0 0 0 0
0 0 0 0 0


F2 =


0 0 0 0 0
0 0 β1S
N
+
β
′
1β1RT
N
0 β1S
N
+
β
′
1β1RT
N
0 0 0 0 0
0 0 0 0 0
β2ηS
N
+ β2ηRT
N
β2S
N
+ β2RT
N
β2S
N
+ β2RT
N
β2S
N
+ β2RT
N
β2Sη
N
+ RT β2η
N
0 0 0 0 0
0 0
β
′
2β1RTH
N
β
′
2
λT
β
′
2β1RTH
N
δβ2ηIT
N
δβ2IT
N
δβ2IT
N
+ ψβ1IH
N
δβ2IT
N
δβ2ηIT
N
+ ψβ1IH
N
0 0 0 0 0
0 0 0 0 0


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and V =
[
V1 V2
]
with
V1 =


λT + λH + µ 0
β1S
N
0 β2S
N
0 k1τ1 + µ 0 0 0
0 −k1 τ2 + δλH + µ+ dT 0
δβ2IT
N
0 −τ1 −τ2 +
β
′
1β1RT
N
β
′
1
λT + λH + µ
β2RT
N
0 0 ψβ1IH
N
0 ρ1 + ψλT + µ
0 0 0 0 −ρ1
0 0 0 0 0
0 0 0 0 0
0 0
β
′
2β1RTH
N
0 0
0 0 0 0 0


V2 =


β2ηS
N
β2S
N
β1S
N
+ β2S
N
β2S
N
β1S
N
+ β2Sη
N
0 0 0 0 0
δβ2ηIT
N
δβ2IT
N
δβ2IT
N
δβ2IT
N
δβ2ηIT
N
β2ηRT
N
β2RT
N
(
β
′
1β1
N
+ β2
N
)
RT
β2RT
N
(
β
′
1β1
N
+ β2η
N
)
RT
−α1 0
ψβ1IH
N
0 ψβ1IH
N
α1 + µ+ dA 0 0 0 0
0 k2 + τ4 + µ 0 0 0
0 −k2 ρ2 + τ3 + µ+ dT 0 −α2
0 −τ4 −τ3 +
β
′
2β1RTH
N
β
′
2
λT + ρ3 + µ
β
′
2β1RTH
N
0 0 −ρ2 −ρ3 α2 + dTA + µ


.
The dominant eigenvalues of the matrix F · V −1 are
R1 =
Λ
Nµ
(
β1
dT + µ+ τ2
)(
k1
k1 + τ1 + µ
)
,
R2 =
Λ
Nµ
β2
(
µ+ α1 + dA + η ρ1
µα1 + (µ+ ρ1)(µ+ dA)
)
.
Thus, the basic reproduction number R0 of the model (1) is given by
R0 = max{R1, R2} .
Note that R1 is the basic reproduction number of the model (1) with IT = A = LTH = ITH =
RTH = AT = 0 (only TB model), and R2 is the basic reproduction number of the model (1) with
LT = IT = RT = LTH = ITH = RTH = AT = 0 (only HIV-AIDS model).
B Appendix: Proof of Theorem 4.1
In this Appendix we provide details of the proof of Theorem 4.1.
Local asymptotical stability of the disease-free equilibrium Σ0. Following Theorem 2
of [15], the disease-free equilibrium, Σ0, is locally asymptotically stable if all the eigenvalues of
the Jacobian matrix of the system (1), here denoted by MT (Σ0), computed at the disease free
equilibrium Σ0, given by (4), have negative real parts.
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The Jacobian matrix of the system (1) at disease free equilibrium Σ0 is given by
MT (Σ0) =
[
MT1 (Σ0) MT2 (Σ0)
]
with
MT1 (Σ0) =


−µ 0 −β1Λ
µN
0 −β2Λ
µN
0 −d1
β1Λ
µN
0 0
0 k1 −d2 0 0
0 τ1 τ2 −µ 0
0 0 0 0 β2Λ
µN
− d3
0 0 0 0 ρ1
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0


and
MT2 (Σ0) =


−
β2ηΛ
µN
−
β2Λ
µN
−
β1Λ
µN
−
β2Λ
µN
−
β2Λ
µN
−
β1Λ
µN
−
β2ηΛ
µN
0 0
β1Λ
µN
0
β1Λ
µN
0 0 0 0 0
0 0 0 0 0
β2ηΛ
µN
+ α1
β2Λ
µN
β2Λ
µN
β2Λ
µN
β2ηΛ
µN
−d4 0 0 0 0
0 −d5 0 0 0
0 k2 −d6 0 α2
0 τ4 τ3 −d7 0
0 0 ρ2 ρ3 −d8


,
where d1 = k1 + τ1 + µ; d2 = τ2 + µ + dT ; d3 = ρ1 + µ; d4 = α1 + µ + dA; d5 = k2 + µ + τ4;
d6 = ρ2 + τ3 + µ+ dT ; d7 = ρ3 + µ; d8 = α2 + dTA + µ. One has
trace [MT (Σ0)] = −2µ− (d1 + d2 + d3 + d4 + d5 + d6 + d7 + d8) < 0
and
det [MT (Σ0)] =
1
N2
(d5 (d6 d7 + dT (α2 + µ) d7 + α2µ d6 + dT dTA d7)
× (Nµ(α1µ+ (µ+ ρ1)(µ+ dA))− β2Λ(α1 + µ+ dA + ρ1η))
× (Nµ(dT + µ+ τ2)(k1 + τ1 + µ)− k1β1Λ) > 0
for
R1 =
Λ
Nµ
(
β1
dT + µ+ τ2
)(
k1
k1 + τ1 + µ
)
< 1
and
R2 =
Λ
Nµ
β2
(
µ+ α1 + dA + η ρ1
µα1 + (µ+ ρ1)(µ+ dA)
)
< 1 .
We have just proved that the disease free equilibrium Σ0 of model (1) is locally asymptotically
stable if R0 < 1, and unstable if either Ri > 1, i = 1, 2.
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Global asymptotical stability of the disease-free equilibrium Σ0. For convenience, let us
rewrite the model system (1) as
dX
dt
= F (X,Z) ,
dZ
dt
= G(X,Z) , G(X, 0) = 0 ,
(8)
where X = (S,RT ) and Z = (LT , IT , IH , A, LTH , ITH , RTH , AT ), with X ∈ R
2
+ denoting (its
components) the number of uninfected individuals and Z ∈ R8+ denoting (its components) the
number of infected individuals including the latent and infectious.
The disease-free equilibrium is denoted by
E0 = (X0, 0) , where X0 =
(
Λ
µ
, 0
)
.
Following [1], if
(H1) E0 is globally asymptotically stable for
dX
dt
= F (X, 0),
(H2) Gˆ(X,Z) > 0 for (X,Z) ∈ Ω, where G(X,Z) = AZ − Gˆ(X,Z), A = DZG(E0, 0) is a Metzler
matrix and Ω is given by (3),
then the fixed point E0 = (X0, 0) is a globally asymptotically stable equilibrium of system (8).
We have
dX
dt
= F (X,Z) =
[
Λ− λTS − λHS − µS
τ1LT + τ2IT − (β
′
1λT + λH + µ)RT
]
,
F (X, 0) =
[
Λ− µS
−µRT
]
,
dZ
dt
= G(X,Z) =


λTS + β
′
1λTRT − (k1 + τ1 + µ)LT ,
k1LT − (τ2 + dT + µ+ δλH)IT ,
λHS − (ρ1 + ψλT + µ)IH + α1A+ λHRT
ρ1IH − α1A− (µ+ dA)A
β
′
2λTRTH − (k2 + τ4 + µ)LTH
δλHIT + ψλT IH + α2AT + k2LTH − (τ3 + ρ2 + µ+ dT )ITH
τ3ITH + τ4LTH − (β
′
2λT + ρ3 + µ)RTH
ρ2ITH + ρ3RTH − (α2 + µ+ dTA)AT ,


,
and G(X, 0) = 0. Thus,
dX
dt
= F (X, 0) =
[
Λ− µS
−µRT
]
,
A = DZG(X0, 0) =
[
D1 D2
]
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with
D1 =


−k1 − τ1 − µ
β1Λ
µN
0 0
k1 −τ2 − µ− dT 0 0
0 0 β2Λ
µN
− ρ1 − µ
β2ηΛ
µN
+ α1
0 0 ρ1 −α1 − µ− dA
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0


,
D2 =


0 β1Λ
µN
0 β1Λ
µN
0 0 0 0
β2Λ
µN
β2Λ
µN
β2Λ
µN
β2ηΛ
µN
0 0 0 0
−k2 − τ4 − µ 0 0 0
k2 −ρ2 − τ3 − µ− dT 0 α2
τ4 τ3 −ρ3 − µ 0
0 ρ2 ρ3 −α2 − dTA − µ


and
Gˆ(X,Z) =


λT
(
Λ
µ
− S − β
′
1
RT
)
−δλH IT
λH
(
Λ
µ
− S − RT − ψIH
)
0
−β
′
2
λTRTH
− (δλH IT + ψλT IH)
β
′
2
λTRTH
0


. (9)
From (9) the condition (H2) is not satisfied, since Gˆ(X,Z) > 0 is not true. Therefore, the
disease-free equilibrium E0 may not be globally asymptotically stable. Following [6], the backward
bifurcation occurs at R0 = 1 and the double endemic equilibria can be supported for Rc < R0 < 1,
where Rc is a positive constant.
Existence and stability of HIV-AIDS free equilibrium ΣT . The expressions for S
⋄, L⋄T ,
I⋄T and R
⋄
T are obtained if we consider a sub-model of (1) for which IH = A = LTH = ITH =
RTH = AT = 0 and the total population N is given by NT = S + LT + IT + RT . The basic
reproduction number of this submodel is given by R1 (5). The existence, uniqueness and local
asymptotic stability of ΣT is proven in [3, Theorem 1].
Existence and stability of TB free equilibrium ΣH . To prove the existence of ΣT , consider
the sub-model of (1) for which LT = IT = RT = LTH = ITH = RTH = AT = 0 and the total
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population NH is given by NH = S + IH +A. The equations of this submodel are

S˙(t) = Λ − λHS(t)− µS(t)
I˙H(t) = λHS(t)− (ρ1 + µ)IH(t) + α1A(t)
A˙(t) = ρ1IH(t)− α1A(t)− (µ+ dA)A ,
(10)
where λH = β2
IH+ηA
NH
. Setting the right hand sides of submodel (10) to zero, we obtain the
endemic equilibrium Σ⋆H = (S
∗, I∗H , A
∗) given by
S⋆ =
Λ
µR2
, I⋆H = (R2 − 1)
µNH(α1 + dA + µ)
β2(α1 + dA + µ+ ηρ1)
, A⋆ = (R2 − 1)
ρ1µNH
β2(α1 + dA + µ+ ηρ1)
,
where I⋆H > 0 and A
⋆ > 0, whenever R2 > 1.
In what follows we prove the local asymptotic stability of the endemic equilibrium Σ⋆H , using
the center manifold theory [2], as described in [4, Theorem 4.1] (see also [15]), considering ART
treatment. The basic reproduction number of this sub-model R2 is given by (6). Chose as
bifurcation parameter, β∗, by solving for β2 from R2 = 1:
β∗ =
µα1 + (µ+ ρ1)(µ+ dA)
α+ dA + µ+ ηρ
.
The submodel (10) has a disease free equilibrium given by Σ∗H0 = (x10, x20, x30) =
(
Λ
µ
, 0, 0
)
.
The Jacobian of the system (10), evaluated at Σ∗H0 and with β2 = β
∗, is given by
J(Σ∗H0) =


−µ −β2 −β2η
0 β2 − ρ− µ β2η + α
0 ρ −α− dA − µ

 . (11)
The eigenvalues of the linearized system (11) are
λ1 = 0, λ2 = −µ and λ3 = −
ηρ(2µ2 + ρ+ dA + α) + dA(2α+ 2µ+ dA) + ρα+ (µ+ α)
2
α+ dA + µ+ ηρ
.
We observe that there is a simple eigenvalue with zero real part and the other two eigenvalues
have negative real part. Thus, the system (10), with β2 = β
∗, has a hyperbolic equilibrium point
and the center manifold theory [2] can be used to analyze the dynamics of the submodel (10) near
β2 = β
∗.
The Jacobian J(Σ∗H0) at β2 = β
∗ has a right eigenvector (associated with the zero eigenvalue)
given by w = [w1, w2, w3]
T , where
w1 = −
(µα1 + (µ+ ρ1)(µ+ dA))w3
ρ1µ
,
w2 =
(α1 + dA + µ)w3
ρ1
,
w3 = w3 > 0 .
Further, J(Σ∗H0) for β2 = β
∗ has a left eigenvector v = [v1, v2, v3] (associated with the zero
eigenvalue), where
v1 = 0 ,
v2 =
v3 (α1 + dA + µ+ ηρ1)
α1 + ηρ1 + µη
,
v3 = v3 > 0 .
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To apply Theorem 4.1 in [4] it is convenient to let fk represent the right-hand side of the kth
equation of the system (10) and let xk be the state variable whose derivative is given by the kth
equation for k = 1, 2, 3. The local stability near the bifurcation point β2 = β
∗ is then determined
by the signs of two associated constants, denoted by a and b, defined (respectively) by
a =
3∑
k,i,j=1
vkwiwj
∂2fk
∂xi∂xj
(0, 0) and b =
3∑
k,i=1
vkwi
∂2fk
∂xi∂φ
(0, 0)
with φ = β2 − β
∗.
For the system (10), the associated partial derivatives at the disease free equilibrium ΣH0 are
given by
∂2f1
∂x22
=
2β∗µ
Λ
,
∂2f1
∂x2∂x3
=
β∗µ(1 + η)
Λ
,
∂2f1
∂x23
=
2β∗µη
Λ
,
∂2f2
∂x22
=
−2β∗µ
Λ
,
∂2f2
∂x2∂x3
=
−β∗µ(1 + η)
Λ
,
∂2f2
∂x23
=
−2β∗µη
Λ
.
It follows from the above expressions that
a = −
v3w
2
3β
∗µ (k1 + µ+ ηρ1)
(
2k21 + 4µk1 + 2µ
2 + ρ1(α1 + η(α1 + µ+ 2ρ1) + dA(1 + η) + µ)
)
ρ21Λ (α1 + ηρ1 + µη)
< 0
with k1 = α1 + dA.
For the sign of b, it can be shown that the associated non-vanishing partial derivatives are
∂2f1
∂x2∂β∗
= −1 ,
∂2f1
∂x3∂β∗
= −η ,
∂2f2
∂x2∂β∗
= 1 ,
∂2f2
∂x3∂β∗
= η .
It also follows from the above expressions that
b =
v3w3 (k1 + µ+ ηρ1) (k1 + µ)
(α1 + ηρ1 + µη) ρ1
+
ηv3w3 (k1 + µ+ ηρ1)
α1 + ηρ1 + µη
> 0 .
Thus, a < 0 and b > 0. Using Theorem 4.1 of [4], the endemic equilibrium Σ⋆H is locally asymp-
totically stable for R2 near 1.
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